This undated, colorized electron microscope image made available by the U.S. National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2, indicated in yellow, emerging from the surface of cells, indicated in blue/pink, cultured in the lab. The sample was isolated from a patient in the U.S. On Thursday, April 21, 2022, scientists reported a U.K. patient with a severely weakened immune system had COVID-19 for almost a year and a half, underscoring the importance of protecting vulnerable people from the coronavirus. (NIAID-RML via AP, File)
By Laura Ungar
A UK patient with a severely weakened immune system had COVID-19 for almost a year and a half, scientists reported, underscoring the importance of protecting vulnerable people from the coronavirus.
There’s no way to know for sure whether it was the longest-lasting COVID-19 infection because not everyone gets tested, especially on a regular basis like this case.
But at 505 days, “it certainly seems to be the longest reported infection," said Dr. Luke Blagdon Snell, an infectious disease expert at the Guy’s & St. Thomas' NHS Foundation Trust.
Their study investigated which mutations arise — and whether variants evolve — in people with super long infections. It involved nine patients who tested positive for the virus for at least eight weeks. All had weakened immune systems from organ transplants, HIV, cancer or treatment for other illnesses. None were identified for privacy reasons.
Repeated tests showed their infections lingered for an average of 73 days. Two had the virus for more than a year. Previously, researchers said, the longest-known case that was confirmed with a PCR test lasted 335 days.
Persistent COVID-19 is rare and different from long COVID.
“In long COVID, it’s generally assumed the virus has been cleared from your body but the symptoms persist,” Snell said. “With persistent infection, it represents ongoing, active replication of the virus.”
Each time researchers tested patients, they analyzed the genetic code of the virus to make sure it was the same strain and that people didn't get COVID-19 more than once. Still, genetic sequencing showed that the virus changed over time, mutating as it adapted.
The mutations were similar to the ones that later showed up in widespread variants, Snell said, although none of the patients spawned new mutants that became variants of concern. There's also no evidence they spread the virus to others.
The person with the longest known infection tested positive in early 2020, was treated with the antiviral drug remdesiver and died sometime in 2021. Researchers declined to name the cause of death and said the person had several other illnesses.
Five patients survived. Two cleared the infection without treatment, two cleared it after treatment and one still has COVID-19. At the last follow-up earlier this year, that patient’s infection had lasted 412 days.
Researchers hope more treatments will be developed to help people with persistent infections beat the virus.
“We do need to be mindful that there are some people who are more susceptible to these problems like persistent infection and severe disease,” Snell said.
Although persistent infections are rare, experts said there are many people with compromised immune systems who remain at risk of severe COVID-19 and who are trying to stay safe after governments lifted restrictions and masks started coming off. And it's not always easy to know who they are, said Dr. Wesley Long, a pathologist at Houston Methodist in Texas, who was not part of the research.
“Masking in crowds is a considerate thing to do and a way we can protect others,” he said.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
Direct health care company Nomi Health recently raised $110 million in a Series A round. Nomi Health lets public and private organizations directly purchase healthcare at reduced costs, and pay providers in real-time. It also delivers healthcare directly to under-served communities via its fleet of mobile care units, which the company says is the largest in the country. Nomi Health says its mission is to improve the health care experience for all Americans. Nomi Health CEO Mark Newman joined Cheddar News' Closing Bell to discuss.
The airline industry says it is contending with staff shortages that threaten to hamper operations amid the COVID resurgence, andDelta Airlines CEO Ed Bastian called on the CDC to revise its guidance for vaccinated workers who test positive from a 10-day quarantine to just five. Chuck Liberman, chief investment officer and managing partner at Advisors Capital Management LLC, joined Cheddar to talk about the current guidance on isolation and why he believes the omicron variant calls for more relaxed guidance given its reportedly mild symptoms.
The boys discuss President Biden's plans to send out free rapid tests as the testing supply chain starts to buckle ahead of the holidays. Also, why aren't Americans having more babies, and The Matrix returns.
NASA is launching its new generation of space telescopes just before Christmas. The James Webb Space Telescope, set to launch on December 24th, will succeed the Hubble space telescope as the world's most powerful complex space observatory. The project has been 30 years in the making and is one of the most highly anticipated space science missions of the 21st century. Klaus Pontoppidan, astronomer and JWST Project Scientist at the Space Telescope Science Institute joined Cheddar's Opening Bell to discuss.
With Omicron becoming the dominant COVID-19 variant in the U.S., President Joe Biden announced that he will make 500 million rapid tests available to Americans in January 2022. Cheddar News speaks with Dr. Shereef Elnahal, President and CEO of University Hospital why testing is key to combatting the spread of the virus.
